Inflammatory Biomarkers in Atrial Fibrillation.
Atrial fibrillation
C-reactive protein
anti-inflammatory drugs
inflammation
inflammatory biomarkers
interleukins
statins.
Journal
Current medicinal chemistry
ISSN: 1875-533X
Titre abrégé: Curr Med Chem
Pays: United Arab Emirates
ID NLM: 9440157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
09
2016
revised:
20
11
2016
accepted:
02
12
2016
pubmed:
28
7
2017
medline:
18
5
2019
entrez:
28
7
2017
Statut:
ppublish
Résumé
During the last few years, a significant number of studies have attempted to clarify the underlying mechanisms that lead to the presentation of atrial fibrillation (AF). Inflammation is a key component of the pathophysiological processes that lead to the development of AF; the amplification of inflammatory pathways triggers AF, and, in tandem, AF increases the inflammatory state. Indeed, the plasma levels of several inflammatory biomarkers are elevated in patients with AF. In addition, the levels of specific inflammatory biomarkers may provide information regarding to the AF duration. Several small studies have assessed the role of anti-inflammatory treatment in atrial fibrillation but the results have been contradictory. Large-scale studies are needed to evaluate the role of inflammation in AF and whether anti-inflammatory medications should be routinely administered to patients with AF.
Identifiants
pubmed: 28748764
pii: CMC-EPUB-85021
doi: 10.2174/0929867324666170727103357
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Biomarkers
0
Interleukins
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
837-854Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.